Laser-guided Treatment, VTP, May Be Alternative to Monitoring or Surgery for Low-risk Prostate Cancers

Laser-guided Treatment, VTP, May Be Alternative to Monitoring or Surgery for Low-risk Prostate Cancers
An non-surgical approach, called vascular-targeted photodynamic therapy (VTP), may be a new way of treating early stage and localized prostate cancer, according to a study published in The Lancet Oncology. The technique involves injecting a light-sensitive drug, called WST11, into the bloodstream and then activating it with a laser, via optical fibers inserted directly into the prostate. The laser causes WST11 to release free radicals that kill surrounding cancerous cells in the prostate tissue. A Phase 3 clinical trial (NCT01310894) led by Mark Emberton, dean of Medical Sciences at University College London and a consultant urologist at University College London Hospitals, and funded by Steba Biotech, tested the approach in 413 patients with low-risk prostate cancer at 47 different sites in 10 countries across Europe. Results of the study, “Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial,” showed that almost half (49%) of the men treated with VTP went into complete remission, compared to 13.5 percent in the control group under active surveillance. In addition, only 6 percent of the patients in the VTP group required radical therapy, which involves complete removal or irradiation of the prostate, compared to 30 percent
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *